As we advance our lead program, VT3989, through late-stage development in mesothelioma and other solid tumors, we are actively seeking strategic partnerships with biopharmaceutical companies, research institutions and investors who share our vision of accelerating innovation and delivering life-changing therapies to patients worldwide. Together, we can make a lasting impact for patients with cancer.